PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-129.30%
Revenue decline while VET shows 20.22% growth. Joel Greenblatt would examine competitive position erosion.
-193.49%
Cost reduction while VET shows 27.18% growth. Joel Greenblatt would examine competitive advantage.
7.42%
Gross profit growth below 50% of VET's 15.42%. Michael Burry would check for structural issues.
-466.66%
Both companies show margin pressure. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
G&A reduction while VET shows 2.56% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-12.15%
Other expenses reduction while VET shows 0.00% growth. Joel Greenblatt would examine efficiency.
-12.19%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-142.19%
Total costs reduction while VET shows 9.10% growth. Joel Greenblatt would examine advantage.
19.35%
Interest expense growth while VET reduces costs. John Neff would investigate differences.
-24.50%
Both companies reducing D&A. Martin Whitman would check industry patterns.
9.64%
EBITDA growth 50-75% of VET's 13.61%. Martin Whitman would scrutinize operations.
-462.28%
Both companies show margin pressure. Martin Whitman would check industry conditions.
110.61%
Operating income growth exceeding 1.5x VET's 66.60%. David Dodd would verify competitive advantages.
-818.88%
Operating margin decline while VET shows 38.58% growth. Joel Greenblatt would examine position.
32.82%
Other expenses growth while VET reduces costs. John Neff would investigate differences.
665.12%
Pre-tax income growth exceeding 1.5x VET's 96.26%. David Dodd would verify competitive advantages.
-2711.62%
Pre-tax margin decline while VET shows 63.26% growth. Joel Greenblatt would examine position.
-1627.78%
Both companies reducing tax expense. Martin Whitman would check patterns.
2444.00%
Net income growth exceeding 1.5x VET's 589.13%. David Dodd would verify competitive advantages.
-8783.61%
Net margin decline while VET shows 473.25% growth. Joel Greenblatt would examine position.
2720.00%
EPS growth exceeding 1.5x VET's 516.00%. David Dodd would verify competitive advantages.
2720.00%
Diluted EPS growth exceeding 1.5x VET's 460.00%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-0.03%
Diluted share reduction while VET shows 11.10% change. Joel Greenblatt would examine strategy.